Clonazolam Stats & Data
O=N(=O)c1ccc2n3c(C)nnc3CN=C(c3ccccc3Cl)c2c1XJRGLCAWBRZUFC-UHFFFAOYSA-NInteraction Warnings
This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
It is dangerous to combine benzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified disinhibition as well as other effects.
Pharmacology
DrugBankDescription
Quahog, unspecified allergenic extract is used in allergenic testing.
History & Culture
Clonazolam was first synthesized in 1971 by The Upjohn Company, the pharmaceutical corporation that would later bring alprazolam (Xanax) to market. In the original research, the compound was described as the most active substance in the series of triazolobenzodiazepines tested. Despite this notable potency and coverage by patents, the drug was never developed for clinical use or marketed. The compound remained largely obscure until reports of its use as a research chemical began appearing online around 2013, making it one of the more recently emerged designer benzodiazepines. The European Monitoring Centre for Drugs and Drug Addiction was first notified of clonazolam's presence in the European Union in January 2015, following a report from Sweden. By 2016, detection of novel benzodiazepines had risen markedly across Europe, with over 300,000 tablets containing designer benzodiazepines—including clonazolam, diclazepam, etizolam, and flubromazolam—seized in 2015, nearly double the figure from the previous year. Clonazolam's extreme potency has made it a subject of particular concern within online drug communities. Early forum discussions frequently noted incidents of blackouts and the rapid development of dependence, establishing a reputation that distinguished it from other designer benzodiazepines in circulation. Its microgram-range activity led to distribution methods uncommon for benzodiazepines, with the substance appearing on blotter paper and in volumetrically prepared solutions rather than as raw powder.
Subjective Effect Notes
physical: The physical effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage.
cognitive: The cognitive effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of clonazolam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
Effect Profile
Curated + 28 ReportsStrong anxiolysis, cognitive impairment, and sedation with moderate euphoria
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 28 experience reports (28 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 7
Adverse Effects 3
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 63 individual dose entries
Oral (n=41)
Rectal (n=5)
Sublingual (n=6)
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 23 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Australia | Schedule 9 | Classified as a Schedule 9 prohibited substance under federal law. Substances in this category are considered to have no recognized therapeutic value and high potential for misuse. |
| Canada | Schedule 4 | Listed under Schedule 4 of the Controlled Drugs and Substances Act, restricting possession and distribution without authorization. |
| Czech Republic | Schedule I (List 4) | Controlled under § 1, d), 2. of Nařízení vlády č. 463/2013 Sb. Use is restricted exclusively to limited research purposes or very limited therapeutic applications. |
| Germany | Anlage II BtMG | Controlled under the Betäubungsmittelgesetz (Narcotics Act) since November 11, 2021. Production and import with intent to distribute, administration to another person, possession, and trading are prohibited. |
| Japan | Controlled | Regulated under the Pharmaceutical Affairs Law. Possession and sale are illegal without authorization. |
| Netherlands | List 2 (Opiumwet) | Controlled as a List 2 substance under the Opium Law. Possession, production, and distribution are illegal. |
| Poland | NPS Class | Classified as a New Psychoactive Substance under Polish drug legislation. Possession and distribution are prohibited. |
| Russia | Schedule III | Listed as a Schedule III controlled substance since 2017. Subject to restrictions on production, distribution, and possession. |
| Sweden | Hazardous Substance | Classified as an addictive substance following a recommendation by Sweden's public health agency on June 1, 2015. Production, import, trading, and possession require special authorization. |
| Switzerland | Verzeichnis E | Specifically named as a controlled substance under Verzeichnis E (List E) of Swiss narcotics legislation. |
| United Kingdom | Class C | Classified as a Class C drug under the May 2017 amendment to the Misuse of Drugs Act 1971, alongside several other designer benzodiazepines. Possession, production, and supply are criminal offenses. |
| United States | Schedule I | Temporarily placed under Schedule I of the Controlled Substances Act effective July 26, 2023, following DEA consideration announced in December 2022. The temporary scheduling has been extended until July 26, 2026. Not FDA approved for human consumption. Several states enacted their own scheduling prior to federal action, including Virginia, Oregon, and Minnesota (since August 2020). |